quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·18d
PRRelease
Actinium Pharmaceuticals Inc. (Delaware) logo

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

ATNM· Actinium Pharmaceuticals Inc. (Delaware)
Health Care
Original source

Companies

  • ATNM
    Actinium Pharmaceuticals Inc. (Delaware)
    Health Care

Recent analyst ratings

  • Aug 7UpdateB. Riley Securities$2.00
  • May 14UpdateStephens$25.00
  • Sep 6UpdateHSBC Securities$11.60
  • Feb 21UpdateWilliam Blair-
  • Sep 8UpdateCantor Fitzgerald$20.00
  • Aug 25UpdateB. Riley Securities$16.00

Related

  • PR2d
    Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
  • PR2d
    Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
  • SEC24d
    SEC Form 10-K filed by Actinium Pharmaceuticals Inc. (Delaware)
  • SEC28d
    Amendment: Actinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
  • PR66d
    Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
  • SEC69d
    Actinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Leadership Update
  • PR133d
    Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
  • PR144d
    Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022